Expression of the HFE allelic variant H63D in SH-SY5Y cells affects tau phosphorylation at serine residues

Neurobiology of Aging

Volumn 32, Issue 8, 2011, Pages 1409-1419

  Hall, Eric C ^a   Lee, Sang Y ^a   Mairuae, Nootchanat ^b   Simmons, Zachary ^a   Connor, James R ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Alzheimer's disease; GSK 3 ; HFE; Iron; Oxidative stress; Phosphorylation; Tau

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA; IRON; IRON CHELATING AGENT; SERINE; TAU PROTEIN; TROLOX C;

AMINO ACID SEQUENCE; ARTICLE; CANCER CELL CULTURE; CELL LEVEL; CONTROLLED STUDY; ENZYME ACTIVITY; GENE; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HFE GENE; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; UPREGULATION;

ALLELES; ANTIOXIDANTS; CELL LINE, TUMOR; CHROMANS; GENETIC VARIATION; GLYCOGEN SYNTHASE KINASE 3; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IRON; MEMBRANE PROTEINS; NEUROBLASTOMA; NEURODEGENERATIVE DISEASES; OXIDATIVE STRESS; PHOSPHORYLATION; SERINE; TAU PROTEINS;

EID: 79959590338     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2009.08.012     Document Type: Article

References (35)

1. Adams P.C., Reboussin D.M., Barton J.C., McLaren C.E., Eckfeldt J.H., McLaren G.D., Dawkins F.W., Acton R.T., Harris E.L., Gordeuk V.R., Leiendecker-Foster C., Speechley M., Snively B.M., Holup J.L., Thomson E., Sholinsky P. Hemochromatosis and iron-overload screening in a racially diverse population. N. Engl. J. Med. 2005, 352(17):1769-1778.
2. Arosio P., Levi S. Ferritin, iron homeostasis, and oxidative damage. Free Radic. Biol. Med. 2002, 33(4):457-463.
3. Ballatore C., Lee V.M., Trojanowski J.Q. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat. Rev. Neurosci. 2007, 8(9):663-672.
4. Berg D., Hoggenmuller U., Hofmann E., Fischer R., Kraus M., Scheurlen M., Becker G. The basal ganglia in haemochromatosis. Neuroradiology 2000, 42(1):9-13.
5. Borie C., Gasparini F., Verpillat P., Bonnet A.M., Agid Y., Hetet G., Brice A., Durr A., Grandchamp B. Association study between iron-related genes polymorphisms and Parkinson's disease. J. Neurol. 2002, 249(7):801-804.
6. Bush A.I. The metallobiology of Alzheimer's disease. Trends Neurosci. 2003, 26(4):207-214.
7. Connor J.R., Lee S.Y. HFE mutations and Alzheimer's disease. J. Alzheimers Dis. 2006, 10(2-3):267-276.
8. Connor J.R., Milward E.A., Moalem S., Sampietro M., Boyer P., Percy M.E., Vergani C., Scott R.J., Chorney M. Is hemochromatosis a risk factor for Alzheimer's disease?. J. Alzheimers Dis. 2001, 3(5):471-477.
9. De Sarno P., Li X., Jope R.S. Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology 2002, 43(7):1158-1164.
10. Dekker M.C., Giesbergen P.C., Njajou O.T., van Swieten J.C., Hofman A., Breteler M.M., van Duijn C.M. Mutations in the hemochromatosis gene (HFE), Parkinson's disease and parkinsonism. Neurosci. Lett. 2003, 348(2):117-119.
11. Egana J.T., Zambrano C., Nunez M.T., Gonzalez-Billault C., Maccioni R.B. Iron-induced oxidative stress modify tau phosphorylation patterns in hippocampal cell cultures. Biometals 2003, 16(1):215-223.
12. Ellervik C., Tybjaerg-Hansen A., Appleyard M., Sillesen H., Boysen G., Nordestgaard B.G. Hereditary hemochromatosis genotypes and risk of ischemic stroke. Neurology 2007, 68(13):1025-1031.
13. Feder J.N., Penny D.M., Irrinki A., Lee V.K., Lebron J.A., Watson N., Tsuchihashi Z., Sigal E., Bjorkman P.J., Schatzman R.C. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc. Natl. Acad. Sci. U.S.A. 1998, 95(4):1472-1477.
14. Fornai F., Longone P., Cafaro L., Kastsiuchenka O., Ferrucci M., Manca M.L., Lazzeri G., Spalloni A., Bellio N., Lenzi P., Modugno N., Siciliano G., Isidoro C., Murri L., Ruggieri S., Paparelli A. Lithium delays progression of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U.S.A. 2008, 105(6):2052-2057.
15. Goodall E.F., Greenway M.J., van Marion I., Carroll C.B., Hardiman O., Morrison K.E. Association of the H63D polymorphism in the hemochromatosis gene with sporadic ALS. Neurology 2005, 65(6):934-937.
16. Grimes C.A., Jope R.S. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog. Neurobiol. 2001, 65(4):391-426.
17. Guerreiro R.J., Bras J.M., Santana I., Januario C., Santiago B., Morgadinho A.S., Ribeiro M.H., Hardy J., Singleton A., Oliveira C. Association of HFE common mutations with Parkinson's disease, Alzheimer's disease and mild cognitive impairment in a Portuguese cohort. BMC Neurol. 2006, 6:24.
18. Haque N., Tanaka T., Iqbal K., Grundke-Iqbal I. Regulation of expression, phosphorylation and biological activity of tau during differentiation in SY5Y cells. Brain Res. 1999, 838(1-2):69-77.
19. Iqbal K., Grundke-Iqbal I. Discoveries of tau, abnormally hyperphosphorylated tau and others of neurofibrillary degeneration: a personal historical perspective. J. Alzheimers Dis. 2006, 9(3 Suppl.):219-242.
20. Jamsa A., Hasslund K., Cowburn R.F., Backstrom A., Vasange M. The retinoic acid and brain-derived neurotrophic factor differentiated SH-SY5Y cell line as a model for Alzheimer's disease-like tau phosphorylation. Biochem. Biophys. Res. Commun. 2004, 319(3):993-1000.
21. Lee S.Y., Patton S.M., Henderson R.J., Connor J.R. Consequences of expressing mutants of the hemochromatosis gene (HFE) into a human neuronal cell line lacking endogenous HFE. FASEB J. 2007, 21(2):564-576.
22. Lee V.M., Goedert M., Trojanowski J.Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 2001, 24:1121-1159.
23. Li T., Hawkes C., Qureshi H.Y., Kar S., Paudel H.K. Cyclin-dependent protein kinase 5 primes microtubule-associated protein tau site-specifically for glycogen synthase kinase 3beta. Biochemistry 2006, 45(10):3134-3145.
24. Mazanetz M.P., Fischer P.M. Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat. Rev. Drug Discov. 2007, 6(6):464-479.
25. Mitchell R., Freeman W., Randazzo W., Stephens H., Beard J., Simmons Z., Connor J. A CSF biomarker panel for identification of patients with amyotrophic lateral sclerosis. Neurology 2009, 72(1):14-19.
26. Percy M., Moalem S., Garcia A., Somerville M.J., Hicks M., Andrews D., Azad A., Schwarz P., Zavareh R.B., Birkan R., Choo C., Chow V., Dhaliwal S., Duda V., Kupferschmidt A.L., Lam K., Lightman D., Machalek K., Mar W., Nguyen F., Rytwinski P.J., Svara E., Tran M., Wheeler K., Yeung L., Zanibbi K., Zener R., Ziraldo M., Freedman M. Involvement of ApoE E4 and H63D in sporadic Alzheimer's disease in a folate-supplemented Ontario population. J. Alzheimers Dis. 2008, 14(1):69-84.
27. Plattner F., Angelo M., Giese K.P. The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. J. Biol. Chem. 2006, 281(35):25457-25465.
28. Pulliam J.F., Jennings C.D., Kryscio R.J., Davis D.G., Wilson D., Montine T.J., Schmitt F.A., Markesbery W.R. Association of HFE mutations with neurodegeneration and oxidative stress in Alzheimer's disease and correlation with APOE. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2003, 119B(1):48-53.
29. Restagno G., Lombardo F., Ghiglione P., Calvo A., Cocco E., Sbaiz L., Mutani R., Chio A. HFE H63D polymorphism is increased in patients with amyotrophic lateral sclerosis of Italian origin. J. Neurol. Neurosurg. Psychiatry 2007, 78(3):327.
30. Sengupta A., Novak M., Grundke-Iqbal I., Iqbal K. Regulation of phosphorylation of tau by cyclin-dependent kinase 5 and glycogen synthase kinase-3 at substrate level. FEBS Lett. 2006, 580(25):5925-5933.
31. Sutedja N.A., Sinke R.J., Van Vught P.W., Van der Linden M.W., Wokke J.H., Van Duijn C.M., Njajou O.T., Van der Schouw Y.T., Veldink J.H., Van den Berg L.H. The association between H63D mutations in HFE and amyotrophic lateral sclerosis in a Dutch population. Arch. Neurol. 2007, 64(1):63-67.
32. Waalen J., Nordestgaard B.G., Beutler E. The penetrance of hereditary hemochromatosis. Best Pract. Res. Clin. Haematol. 2005, 18(2):203-220.
33. Wang X.S., Lee S., Simmons Z., Boyer P., Scott K., Liu W., Connor J. Increased incidence of the Hfe mutation in amyotrophic lateral sclerosis and related cellular consequences. J. Neurol. Sci. 2004, 227(1):27-33.
34. Yen A.A., Simpson E.P., Henkel J.S., Beers D.R., Appel S.H. HFE mutations are not strongly associated with sporadic ALS. Neurology 2004, 62(9):1611-1612.
35. Zecca L., Youdim M.B., Riederer P., Connor J.R., Crichton R.R. Iron, brain ageing and neurodegenerative disorders. Nat. Rev. Neurosci. 2004, 5(11):863-873.